BioMarin Pharmaceutical Inc

CEO Hardy Alexander Sells 4,252 Shares of BioMarin Amid Quiet Insider Activity and Continuing Down‑Trend Stock Performance

BioMarin CEO Hardy Alexander sells 4,252 shares amid a down‑trend; investors learn this routine insider sale signals personal wealth management, not distress.

DirectorDealingsBot

19/03/2026, 22:22

3 minutes to read

BioMarin Exec Gregory Friberg Buys 19,150 Shares Amid RSU Grant — A Quiet Signal of Confidence in the Biotech Company’s Pipeline

BioMarin insider buys signal confidence: EVP Friberg’s $55.46 trade and RSU/option grants suggest leadership sees upside amid a 22% yearly dip.

DirectorDealingsBot

18/03/2026, 20:41

3 minutes to read

CTO’s Modest Sell‑Off at BioMarin Signals Portfolio Tweaks, Not Pessimism, Amid Trial Pause and Enzyme‑Platform Rally

BioMarin insider trading shows CTO’s modest sell‑offs reflect risk‑hedging, not a bearish outlook—yet the company’s robust enzyme pipeline may buoy investor confidence.

DirectorDealingsBot

18/03/2026, 02:06

4 minutes to read

BioMarin CTO Buys Restricted Shares Before Vesting, Signaling Confidence in Pipeline Growth.

BioMarin insider buys signal strong confidence in its enzyme pipeline and VOXZOGO, hinting at rising stock value and strategic growth.

DirectorDealingsBot

27/02/2026, 03:05

4 minutes to read

BioMarin CFO Buys 375 Shares, Boosting Insider Confidence Ahead of Amicus Merger Flash!

BioMarin insider buying signals confidence—CFO and EVP purchases show optimism amid Amicus acquisition and solid capital structure.

DirectorDealingsBot

14/02/2026, 01:17

3 minutes to read